Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.16 Million CAD | 3.26% |
| 2022 | 2.09 Million CAD | -18.37% |
| 2021 | 2.56 Million CAD | 101.29% |
| 2020 | 1.27 Million CAD | -20.64% |
| 2019 | 1.6 Million CAD | 26.87% |
| 2018 | 1.26 Million CAD | 45.59% |
| 2017 | 869.88 Thousand CAD | 22.64% |
| 2016 | 709.31 Thousand CAD | 693.81% |
| 2015 | 89.35 Thousand CAD | -44.15% |
| 2014 | 160 Thousand CAD | -13.32% |
| 2013 | 184.59 Thousand CAD | -24.6% |
| 2012 | 244.81 Thousand CAD | 18.72% |
| 2011 | 206.2 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.32 Million CAD | -9.21% |
| 2024 Q1 | 2.56 Million CAD | 18.39% |
| 2024 Q3 | 2.33 Million CAD | 0.38% |
| 2023 Q2 | 2.24 Million CAD | -18.95% |
| 2023 Q3 | 2.17 Million CAD | -3.3% |
| 2023 Q4 | 2.16 Million CAD | -0.48% |
| 2023 FY | 2.16 Million CAD | 3.26% |
| 2023 Q1 | 2.77 Million CAD | 32.38% |
| 2022 Q3 | 2.34 Million CAD | 8.08% |
| 2022 Q4 | 2.09 Million CAD | -10.81% |
| 2022 FY | 2.09 Million CAD | -18.37% |
| 2022 Q1 | 2.16 Million CAD | -15.84% |
| 2022 Q2 | 2.17 Million CAD | 0.62% |
| 2021 Q1 | 1.8 Million CAD | 41.89% |
| 2021 Q2 | 3.21 Million CAD | 77.49% |
| 2021 Q3 | 3.04 Million CAD | -5.05% |
| 2021 Q4 | 2.56 Million CAD | -15.83% |
| 2021 FY | 2.56 Million CAD | 101.29% |
| 2020 Q3 | 1.31 Million CAD | -14.44% |
| 2020 Q2 | 1.53 Million CAD | -5.15% |
| 2020 Q1 | 1.62 Million CAD | 0.98% |
| 2020 FY | 1.27 Million CAD | -20.64% |
| 2020 Q4 | 1.27 Million CAD | -3.16% |
| 2019 Q2 | 1.21 Million CAD | 3.84% |
| 2019 FY | 1.6 Million CAD | 26.87% |
| 2019 Q4 | 1.6 Million CAD | 19.48% |
| 2019 Q3 | 1.34 Million CAD | 11.14% |
| 2019 Q1 | 1.16 Million CAD | -7.99% |
| 2018 Q3 | 1.14 Million CAD | 13.43% |
| 2018 Q1 | 951.1 Thousand CAD | 9.34% |
| 2018 FY | 1.26 Million CAD | 45.59% |
| 2018 Q4 | 1.26 Million CAD | 10.16% |
| 2018 Q2 | 1.01 Million CAD | 6.56% |
| 2017 Q3 | 695.78 Thousand CAD | 17.89% |
| 2017 FY | 869.88 Thousand CAD | 22.64% |
| 2017 Q4 | 869.88 Thousand CAD | 25.02% |
| 2017 Q1 | 288.47 Thousand CAD | -59.33% |
| 2017 Q2 | 590.21 Thousand CAD | 104.6% |
| 2016 FY | 709.31 Thousand CAD | 693.81% |
| 2016 Q3 | 70.25 Thousand CAD | -4.97% |
| 2016 Q2 | 73.92 Thousand CAD | -15.49% |
| 2016 Q4 | 709.31 Thousand CAD | 909.65% |
| 2016 Q1 | 87.47 Thousand CAD | -2.11% |
| 2015 Q4 | 89.35 Thousand CAD | -2.53% |
| 2015 Q2 | 94.48 Thousand CAD | -40.18% |
| 2015 Q1 | 157.94 Thousand CAD | -1.29% |
| 2015 FY | 89.35 Thousand CAD | -44.15% |
| 2015 Q3 | 91.67 Thousand CAD | -2.97% |
| 2014 Q4 | 160 Thousand CAD | -1.24% |
| 2014 Q1 | 178.09 Thousand CAD | -3.52% |
| 2014 Q2 | 179.11 Thousand CAD | 0.58% |
| 2014 Q3 | 162.02 Thousand CAD | -9.54% |
| 2014 FY | 160 Thousand CAD | -13.32% |
| 2013 Q2 | 224.47 Thousand CAD | -6.0% |
| 2013 Q4 | 184.59 Thousand CAD | -13.09% |
| 2013 FY | 184.59 Thousand CAD | -24.6% |
| 2013 Q3 | 212.4 Thousand CAD | -5.38% |
| 2013 Q1 | 238.81 Thousand CAD | -2.45% |
| 2012 FY | 244.81 Thousand CAD | 18.72% |
| 2012 Q2 | 263.41 Thousand CAD | 0.0% |
| 2012 Q4 | 244.81 Thousand CAD | -2.38% |
| 2012 Q3 | 250.78 Thousand CAD | -4.8% |
| 2011 FY | 206.2 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 1.08 Million CAD | -99.191% |
| CanadaBis Capital Inc. | 22.96 Million CAD | 90.578% |
| Decibel Cannabis Company Inc. | 142.98 Million CAD | 98.487% |
| Delivra Health Brands Inc. | 10.05 Million CAD | 78.475% |
| Entourage Health Corp. | 31.39 Million CAD | 93.108% |
| Lifeist Wellness Inc. | 13.39 Million CAD | 83.852% |
| Cannara Biotech Inc. | 141.52 Million CAD | 98.471% |
| Medicure Inc. | 28.05 Million CAD | 92.289% |
| PharmaCielo Ltd. | 22.28 Million CAD | 90.293% |
| Rubicon Organics Inc. | 54.89 Million CAD | 96.058% |
| BioSyent Inc. | 41.52 Million CAD | 94.79% |